Current use of drains and management of seroma following mastectomy and axillary surgery: results of a United Kingdom national practice survey K. FairhurstK. Robertson behalf of the Diamond Study Collaborative Preclinical study Open access 25 October 2023 Pages: 187 - 196
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer Ozge GumusayLaura A. HuppertHope S. Rugo Clinical trial Open access 10 October 2023 Pages: 197 - 204
Quantitative assessment of breast volume changes after whole-breast irradiation for breast cancer using breast auto-segmentation Tae Hoon LeeSang Hee AhnHaeyoung Kim Clinical trial 13 October 2023 Pages: 205 - 214
Breast cancer outcomes based on method of detection in community-based breast cancer registry Debbie Lee BennettAndrea Marie WinterLinda Moy Clinical trial 25 October 2023 Pages: 215 - 224
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer Takayuki IwamotoNaoki NiikuraShigehira Saji Clinical trial 25 October 2023 Pages: 225 - 234
Treatment utilization and effectiveness of neoadjuvant chemotherapy comparing men and women diagnosed with breast cancer: a Swedish retrospective cohort study Aglaia SchizaIrma FredrikssonAntonios Valachis Epidemiology Open access 09 October 2023 Pages: 235 - 243
The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB) Harriet T RothschildElle N ClellandRita A Mukhtar Epidemiology Open access 13 October 2023 Pages: 245 - 256
Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer Walter Carbajal-OchoaDaniela C. Bravo-SolarteJesus D. Anampa Epidemiology 13 October 2023 Pages: 257 - 269
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients Stephanie GuStephen DuszaMario E. Lacouture Epidemiology Open access 13 October 2023 Pages: 271 - 280
Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system Veronica C. ShimRobin J. BakerLaurel A. Habel Epidemiology Open access 17 October 2023 Pages: 281 - 289
The largest genome-wide association study for breast cancer in Taiwanese Han population Yu-Ching HsuHung-Lin ChenFuu-Jen Tsai Epidemiology 18 October 2023 Pages: 291 - 306
Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus Anna P. SokolenkoElvina Kh. BakaevaEvgeny N. Imyanitov Epidemiology 18 October 2023 Pages: 307 - 315
National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial Christine RogersAdrienne N. CobbChandler S. Cortina Epidemiology 20 October 2023 Pages: 317 - 328
Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer Devon K. CheckBradford E. JacksonClara Lam Epidemiology 24 October 2023 Pages: 329 - 338
The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry Senna W. M. LammersHannah ThurischVivianne C. G. Tjan-Heijnen Epidemiology Open access 25 October 2023 Pages: 339 - 349
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium Mariana BrandãoDiogo Martins-BrancoEvandro de Azambuja Epidemiology 25 October 2023 Pages: 351 - 363
Hereditary cancer testing in a diverse sample across three breast imaging centers Laura WestbrookDarlene MiltenburgJeffrey N. Weitzel Original Laboratory Investigation Open access 20 October 2023 Pages: 365 - 372
Clinicopathological features and prognostic analysis of HER2 low and fibrotic focus in HER2-negative breast cancer Meng YueSi WuYueping Liu Original Laboratory Investigation 16 October 2023 Pages: 373 - 381
Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells Biao HuJiantao Hu Original Laboratory Investigation 17 October 2023 Pages: 383 - 396
Rates of price disclosure associated with the surgical treatment of early-stage breast cancer one year after implementation of federal regulations Shivani A. ShahYuqi ZhangMarcelo Cerullo Original Laboratory Investigation 18 October 2023 Pages: 397 - 406